Elkfork Partners LLC maintained its stake in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,420 shares of the company’s stock at the end of the first quarter. Elkfork Partners LLC owned about 0.16% of Syndax Pharmaceuticals worth $390,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. C WorldWide Group Holding A S purchased a new stake in Syndax Pharmaceuticals during the first quarter valued at approximately $163,000. State Street Corp increased its position in Syndax Pharmaceuticals by 6.5% in the fourth quarter. State Street Corp now owns 58,921 shares of the company’s stock valued at $422,000 after buying an additional 3,599 shares during the period. Alyeska Investment Group L.P. increased its position in Syndax Pharmaceuticals by 33.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 225,000 shares of the company’s stock valued at $1,613,000 after buying an additional 56,228 shares during the period. Finally, Sphera Funds Management LTD. acquired a new position in Syndax Pharmaceuticals during the third quarter valued at approximately $2,521,000. Hedge funds and other institutional investors own 62.22% of the company’s stock.
Shares of Syndax Pharmaceuticals Inc (SNDX) opened at 11.51 on Tuesday. The company’s market cap is $210.12 million. Syndax Pharmaceuticals Inc has a 1-year low of $6.31 and a 1-year high of $18.03. The company’s 50-day moving average is $10.83 and its 200 day moving average is $10.26.
Several research analysts have commented on the stock. FBR & Co initiated coverage on shares of Syndax Pharmaceuticals in a report on Thursday, March 16th. They issued an “outperform” rating and a $27.00 price target for the company. Citigroup Inc set a $24.00 price objective on shares of Syndax Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 19th. Cowen and Company restated an “outperform” rating on shares of Syndax Pharmaceuticals in a research report on Friday, May 19th. Oppenheimer Holdings Inc. set a $25.00 target price on shares of Syndax Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 18th. Finally, ValuEngine upgraded shares of Syndax Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. Syndax Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $23.75. In other news, insider Peter Ordentlich sold 5,000 shares of the stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $15.00, for a total value of $75,000.00. Following the completion of the sale, the insider now directly owns 5,000 shares of the company’s stock, valued at $75,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Receive News & Ratings for Syndax Pharmaceuticals Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Syndax Pharmaceuticals Inc and related companies with MarketBeat.com’s FREE daily email newsletter.